IGC Pharma (IGC) Cash Flow Statement

Click line-items for a historical chart and %

Net income (loss)	-1.01M
Non-cash compensation expense	0
Deferred taxes
Depreciation	195.51K
Non-cash financial expense (including amortization of debt discount)
Share in profits of joint venture
Unrealized exchange losses/(gains)	0
Accounts receivable	-2.46K
Inventories	0
Prepaid expenses and other assets	-4.84K
Trade payables	200.69K
Other current liabilities	-33.41K
Other non – current liabilities
Non-current assets	723
Accrued Expenses	-242.62K
Net cash used in operating activities	-676.73K
Purchase of short term investment
Restricted cash
Net cash provided/(used) by investing activities	-155.35K
Net movement in other short-term borrowings	0
Issuance of equity shares	242.56K
Net cash provided/(used) by financing activities	319.25K
Effects of exchange rate changes on cash and cash equivalents	-38.58K
Net increase/(decrease) in cash and cash equivalents	-551.41K
Cash and cash equivalent at the beginning of the period	1.49M
Cash and cash equivalent at the end of the period	939.29K
Cash paid for interest	18.64K
Cash paid for taxes	0

Entities mentioned with IGC

View All Entities